Endometrial Neoplasms Clinical Trial
Official title:
Near Infrared Fluorescent Technique for Sentinel Lymph Node Mapping in Endometrial Cancer
In endometrial cancer (EC) pelvic and paraaortic lymphadenectomy is performed only in high
risk groups (with approximately 20% of patients having lymph node metastases (LNM)) whereas
no lymphadenectomy is recommended in low risk groups despite 5% LNM. Moreover, preoperative
risk group allocation is known to be erroneous in up to 15% of patients.
A technique identifying sentinel lymph nodes (SLN) in endometrial cancer have the potential
to spare extensive surgery in 80% of high risk patients, identify low risk patients with
nodal metastases, diminish side effects caused by full lymphadenectomy and render some
expensive preoperative risk group allocation measures unnecessary.
A clinically useful SLN technique requires a high technical success rate, a clear definition
of SLN, an algorithm taking into account that metastatic nodes not always accumulate tracer
and a reproducible surgical algorithm. A definition of SLN requires knowledge on lymphatic
anatomy. Unfortunately all tracers, dyes/radiotracers often result in an abundance of
colored/ signaling nodes. Therefore, a definition of a SLN requires identification of
efferent/afferent lymph vessels.
Several publications describe sentinel node techniques in EC with a variety of tracers
(various dyes, radiotracer, alone or in combination). Sentinel nodes are usually described as
"radioactive nodes" or "colored nodes" only with no further discrimination. No study relate
to an anatomical description of lymphatic pathways.
The aims of this study is to systematically display the major anatomical pathways with the
use of ICG and to evaluate a standardized and reproducible SLN surgical algorithm based on
lymphatic anatomy and identification of efferent lymph vessels.
Endometrial cancer is an increasingly common gynecologic malignancy. The cumulative 5-year
survival rate for node negative patients is 94%, 75% in those with metastatic pelvic lymph
nodes only and 38% in patients with pelvic and paraaortic metastases. The proportion of node
positive patients in adequately staged patient materials (usually high risk groups) is
reported in the range of 15-21%. Depending on used risk criteria lymph node metastases occur
in 1.5-7.8% in low risk patients. Some studies show better overall survival after pelvic and
paraaortic lymphadenectomy, whereas other studies show increased complications with no
survival benefit from the lymphadenectomy. Recent articles recommend paraaortic and pelvic
lymp node metastases (LND) in high risk EC but the therapeutic value related to potential
complications of nodal staging in EC is debated as well as how to define risk groups. An
incidence of 0.9-5.2% severe lymphedema and 3.1% chylous ascites requiring treatment has been
described after robotic pelvic and paraaortic lymphadenectomy.
The Sentinel node concept has been studied extensively in other cancer forms, for example
breast and vulvar cancer. With the above mentioned controversy, patients with EC would
benefit tremendously from a functioning Sentinel node concept. Studies using patent blue or
radioactive tracer have not shown satisfactory results. The Da Vinci system (da Vinci®
Surgical System, Intuitive Surgical Inc., Sunnyvale, Ca, USA) with Firefly technique could
make a new concept possible in which major lymphatic drainage can be displayed and learned,
hence allowing a standardization of SLN definitions. In our pilot studies, a reproducible
surgical algorithm has been defined, overcoming and compensating the fact that ICG spreads
quickly to several nodes.
Purpose: To develop a reliable Sentinel node Concept using the Firefly system with ICG in EC
patients based on a defined lymphatic anatomy, a clear definition of a sentinel node and a
reproducible surgical algorithm.
Hypothesis: The Firefly system using ICG enables the use of a Sentinel node concept in EC
patients regardless risk group, so that only patients with pathologically proven lymph nodes
metastases undergo a pelvic and paraaortic lymphadenectomy.
Methods of Research:
375 consecutive EC patients planned for robotic hysterectomy, bilateral salpingo-oophorectomy
and in high risk patients also pelvic and paraaortic lymphadenectomy at Skane University
Hospital, Lund, Sweden are enrolled in this study prospectively after giving written consent.
The study is approved by the regional Institutional Review Board. With extended funding, the
study will be expanded to another University Hospital in Sweden. Data on operative outcome,
operative and postoperative complications, pathology reports and follow up for 24 months are
prospectively collected. The use of Indocyanine green (ICG) and the Firefly system has the
advantage of a fast uptake to lymphatic vessels and lymph nodes. Pilot studies have resulted
in a new surgical method, standardization of operative technique and a clear definition of
the Sentinel lymph node which now enables this study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06409039 -
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
|
||
Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05682950 -
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05974995 -
Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer
|
N/A | |
Recruiting |
NCT03291106 -
Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
|
||
Recruiting |
NCT03291275 -
Survival Outcomes of Uterine Malignancies in Chinese Population
|
N/A | |
Completed |
NCT00341458 -
Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
|
||
Terminated |
NCT05067972 -
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05795244 -
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
|
Phase 2 | |
Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04865289 -
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
|
Phase 3 | |
Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
Terminated |
NCT01969396 -
Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology
|
N/A | |
Completed |
NCT01460979 -
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT05869123 -
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Active, not recruiting |
NCT05588076 -
Endometrial Lesions Predictions
|